🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

PTC Therapeutics, Inc. PTCT R2K

Healthcare · Biotechnology · United States
https://www.ptcbio.com
Company Profile ↓
$78.06
+57.82% 1Y
Mkt Cap$6.48B
P/E-30.73
P/B-29.82
52W High$89.55
52W Low$43.30
Book Value$-2.52
EPS (TTM)$-2.54

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 44.9%.

Consistent Profit Growth

Net profit has compounded at 24.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 22.1% CAGR over the past five years.

Healthy Margins

Operating margin of 16.5% supports profitability.

Recent Developments

  • Dec 2025 Revenue of $1.73B (+114.5% YoY); net profit $682.64M.
  • Trailing 12 Months Year-on-year growth — revenue -76.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 22.1%, profit CAGR 24.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:22.13%
1 Year:-76.80%

Compounded Profit Growth

5 Years:24.74%
1 Year:-

Stock Price Performance

1 Year:+57.82%
6 Months:+0.68%
3 Months:+10.85%
1 Month:+4.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 75% of range
$43.30 $89.55
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)45.25 · Neutral
Price Performance
1M+4.48%
3M+10.85%
6M+0.68%
1Y+57.82%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 44.9%.
  • Compounding revenue at 22.1% over 5 years.
  • Profit CAGR of 24.7% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-30.73
Industry PE
25.41
Forward P/E
28.05
PEG Ratio
-
Book Value
$-2.52
Price to Book
-29.82
P/S
7.54
EV/EBITDA
-337.91
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
22.13%
Profit 5Y
24.74%
Revenue (YoY)
-76.80%
Earnings (YoY)
-

Profitability & Returns

ROCE
44.91%
ROE
-
ROA
-1.54%
Profit Margin
-22.58%
Op Margin
16.54%
Gross Margin
38.32%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-2.54

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
2.29
Current Ratio
2.44
Debt
$2.72B
Total Assets
$2.87B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
7.38%
Chg in Prom Hold
-
FII / Inst Holding
117.72%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$6.48B
Total Revenue (TTM)
$827.11M
EBITDA
$-20.90M
Free Cash Flow
$-418.12M
Operating Cash Flow
$-217.95M
Shares Outstanding
82.95M
Gross Margin
38.32%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PTCT PTC Therapeutics, Inc. R2K 78.06 -30.73 $6.48B 0.00% 44.91% - 22.13% 24.74%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ------------------71.42M-68.26M75.24M118.40M-117.94M116.68M138.74M148.74M165.53M217.13M220.38M213.81M196.58M210.12M186.70M196.79M1.18B178.88M211.01M272.55M
Operating Income -38.07M-38.63M-42.23M-48.20M-38.44M-36.56M-32.06M-24.99M-26.36M-12.50M-30.89M5.45M-16.74M-5.57M-48.23M-45.14M-69.14M-38.76M-60.48M-72.78M-92.99M-187.27M-55.13M-96.37M-98.15M-98.49M-93.08M-86.52M-92.36M-68.19M-117.61M-209.54M-118.16M-45.45M-40.22M-54.51M970.23M-34.96M3.02M44.96M
Net Income -37.91M-38.36M-43.22M-50.95M-41.23M-38.91M-35.17M-26.80M-29.06M-17.48M-33.74M1.27M-19.26M-9.52M-50.97M-48.33M-72.11M-41.79M-60.00M-77.68M-112.69M-181.43M-69.69M-74.35M-128.64M-118.37M-133.62M-126.73M-152.09M-109.31M-138.96M-198.88M-132.97M-91.58M-99.18M-106.65M866.56M-64.85M15.90M-2.81M
Diluted EPS -------------------------1.83-1.68-1.89-1.78-2.13-1.53-1.88-2.66-1.76-1.20-1.29-1.3910.04-0.830.20-0.03
R&D Expense 27.94M28.19M30.64M-31.40M28.83M31.40M-27.36M30.84M30.02M-31.36M32.61M54.37M-52.57M59.98M63.08M-90.11M176.53M93.00M-134.51M125.48M130.84M140.08M157.26M165.46M195.12M185.87M164.21M116.13M132.17M161.41M108.97M112.99M100.16M100.87M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 105.41M33.95M34.70M25.25M36.77M82.70M194.39M264.73M306.98M380.77M538.59M698.80M937.82M806.78M1.73B
Operating Income 30.58M-26.81M-45.40M-99.41M-167.13M-132.06M-64.29M-115.69M-241.16M-431.77M-374.44M-447.41M-439.50M-302.57M866.93M
Net Income 30.90M-26.23M-51.57M-93.75M-170.45M-142.11M-79.00M-128.08M-251.58M-438.16M-523.90M-559.02M-626.60M-363.30M682.64M
Diluted EPS 4.5542.50-5.18-2.97-----4.27-6.64-7.43-7.79-8.37-4.737.78
R&D Expense 58.68M46.14M54.88M79.84M121.82M117.63M117.46M171.98M257.45M477.64M540.68M651.50M666.56M534.48M455.25M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --13.07M151.90M333.22M365.28M269.35M391.65M1.12B1.62B2.21B1.94B1.71B1.90B1.71B2.90B
Total Equity -272.33M-238.60M-99.64M136.54M298.47M226.00M119.58M156.44M350.73M594.33M481.98M1.44M-347.09M-818.55M-1.10B-205.31M
Cash & Equivalents 28.67M28.43M2.73M15.41M49.75M58.02M58.32M111.79M169.50M288.03M208.81M189.72M279.83M594.00M779.71M984.65M
Long Term Debt --438.81K--91.85M98.22M144.97M141.35M293.86M309.14M281.89M571.72M284.21M285.41M-
Total Liabilities --31.89M15.36M34.75M139.28M149.76M235.22M768.50M1.03B1.73B1.94B2.05B2.71B2.80B3.10B
Current Liabilities --28.16M13.13M32.48M45.39M49.62M82.05M166.80M235.86M277.33M509.35M406.24M603.10M580.98M968.43M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----57.27M-124.34M-103.57M-10.06M-27.64M-98.64M-194.07M-251.33M-356.65M-158.42M-107.69M711.20M
Investing Cash Flow ----145.17M-20.81M104.48M13.12M-42.61M-387.24M-561.55M219.18M290.18M-176.74M44.18M-861.98M
Financing Cash Flow ---237.13M154.06M968.00K44.22M131.57M613.21M668.72M20.88M167.95M646.40M255.87M331.09M
Capital Expenditure -165.12K-189.00K-846.00K-4.66M-2.72M-1.78M-3.10M-7.10M-13.76M-17.84M-28.21M-32.02M-28.44M-6.50M-8.86M
Free Cash Flow ----61.94M-127.06M-105.34M-13.16M-34.74M-112.40M-211.91M-279.55M-388.67M-186.86M-114.19M702.34M

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------
Operating Margin % 29.0%-79.0%-130.8%-393.8%-454.6%-159.7%-33.1%-43.7%-78.6%-113.4%-69.5%-64.0%-46.9%-37.5%50.1%
Net Margin % 29.3%-77.3%-148.6%-371.4%-463.6%-171.8%-40.6%-48.4%-82.0%-115.1%-97.3%-80.0%-66.8%-45.0%39.4%
ROE % -13.0%26.3%-37.8%-31.4%-75.4%-118.8%-50.5%-36.5%-42.3%-90.9%-36,432.6%161.1%76.6%33.1%-332.5%
ROCE % -177.7%-32.7%-33.1%-52.2%-60.1%-20.8%-12.1%-17.4%-22.4%-26.2%-34.4%-34.0%-26.9%44.9%

Shareholding Pattern

Insiders
7.38%
Institutions
117.72%
Public Float
-

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PTCT

Google News Sat, 11 Jul 2026

PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNemZ2NmJKdjA1cHZ4OG91SEVlcWpMcGdPYWdBTWdlZ0Vfb0M2UGVXYmFmaWJRNVVRNnlTbG1jS0dTa3FER3h0QTFNQmE1Yy1VYmpzZFMzOHp6UGFaSVNUSi1UbzZhcUZjcFFfRU1wQ2NFN3RRRTFldkRURDdrVlVjaWduQUFwRHlPLUx2eE…

Google News ue, 14 Jul 2026

[144] PTC THERAPEUTICS, INC. SEC Filing - Stock Titan

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPUXoxZjRYZ0hqQWhvZEdEOFdNbnItZ0prTTUyU1lnejU2Zm11OEliLWZVa0lmVFdnV2JkemM2R2t0clRseGdxZ09Xbm5ib2ZNa0d5MTlYWHNYb2RLSlRCcXhuLTF3bDlVMTVXR2dYemVLcGR6bVlBekl6ZnZxT2pOQzUyVFdzTWVuSXNWVX…

Google News ue, 14 Jul 2026

What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNZHRUVUY3WEhRUUN0NWlVclNSOVFmdnhJeUdjTEdHdkFFVjE3OVBBck9DWnFwTlNDQ01aSkJ0b3V0ck9oY3FmNlZLYzJ1MWUyVGY1V2ZEamVRYVhKUVlIcUg0M3RCT2RCdUtZWXNKVFB4MHMzcHhNYTFCSExUYXNjUVA0NzhCU2kyWGVZdX…

Google News Mon, 13 Jul 2026

Insider Sale: Director at $PTCT Sells 5,834 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOQjE5WUc1SkJHcXJaVm1UdV9xYTY0SExxR1BzX3V5bmlqMjNNaDNvM2JVV25BVC10djJIYU1JZmM3RmRSWnFUTGg1OU9JNnNuZHJhV1VfU2NRZHdyY2I5ZDVnTzJ1enhOemFfeTVnUGdOcXd0RFBaNHl1ejA3X1NpUTB5MmJDRnBsTFQ5c2…

Google News Sat, 11 Jul 2026

PTC Therapeutics Inc (PTCT) - MSN

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNLVZTZnhJRW9QV0RRQndfOGJaaTJfblJ4cTRrbnlsVWJuUmp3SjM0Y014RVhRcXQzLVlxNW5pWUF1Z2tmMnUzTjNSQUZOOEV3bVBDVkhNMW1zZDZfT1BYYWxtNW0telBNSkswaTV0a1Jua0JqVGk3YXcycWNrbG9YV2cxT2QzR08wQ1JSMn…

Google News Wed, 08 Jul 2026

PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock - Moomoo

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNaHVBLXJXal9OZGNuT2tqcWJEdS1VLTVNeFhULU5PVTcxMG5zWVY5bmEwSEZnUnQwNURmX1V3ZzNva0FON3BlSTNTU2twdF9Fc25YNXpIWXZ3czcxUUNQQ2sxMmEwNXdsbk8tU3lHVGUzVjRPLW41aUU3ZU13VnFvdDVoVk5xTGZYWnNxeF…

PTCT — Frequently Asked Questions

What is the current share price of PTC Therapeutics, Inc. (PTCT)?

As of 2026-07-14 21:23 PDT, PTC Therapeutics, Inc. (PTCT) trades at $78.06 on NasdaqGS. Its 52-week range is $43.30 to $89.55.

What is the market capitalisation of PTCT?

PTC Therapeutics, Inc. (PTCT) has a market capitalisation of $6.48B on NasdaqGS.

What is the P/E ratio of PTCT?

PTCT trades at a trailing price-to-earnings (P/E) ratio of -30.73. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -29.82.

Is PTCT a good stock to buy?

This page provides a data-driven analysis of PTC Therapeutics, Inc. (PTCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space